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Introduction {#sec001}
============

Aplastic anemia (AA) is a rare, life-threatening hematopoietic stem cell disorder characterized by peripheral blood cytopenia and bone marrow hypoplasia. The prevalence of AA seems to vary in different regions of the world with an annual incidence of two cases per million in Western countries, but a little higher estimated four to seven cases per million in East Asia \[[@pone.0162382.ref001]\].

A large amount of laboratory and clinical data suggest that immune-mediated destruction of hematopoiesis by activated cytotoxic T cells plays an important role in the pathogenesis of AA. The mechanism of activation of cytotoxic T cells is uncertain, but several potential factors related to antigen recognition, susceptibility of immune response, and secretion of cytokines might be involved. Certain human leukocyte antigen (HLA) alleles were suggested to play a role in the activation of autoreactive T-cell clones in patients with AA \[[@pone.0162382.ref002]\]. Till date, potential roles of *HLA-DRB1* polymorphisms have been postulated in many types of autoimmune diseases (e.g., systemic lupus erythematosus and lupus nephritis\[[@pone.0162382.ref003]\], rheumatoid arthritis\[[@pone.0162382.ref004]\]). As with most autoimmune diseases, AA is genetically associated with alleles of the HLA \[[@pone.0162382.ref005]--[@pone.0162382.ref019]\].

Conflicting reports exist regarding the correlation of *HLA-DRB1\*15* and *HLA-DRB1\*15*:*01* polymorphisms with AA. Dhaliwai et al. (2011) demonstrated a significant association of *HLA-DRB1*\*15 polymorphisms with AA, and the odds ratio (*OR*) was 11.09 \[[@pone.0162382.ref009]\]. However, Sun et al. (2004) reported that *HLA-DRB1*\*15 polymorphisms had no significant association with AA \[[@pone.0162382.ref016]\]. Unfortunately, no report about AA risk exists in genome-wide association studies. The present study was perhaps the first meta-analysis discussing the relationship of *HLA-DRB1\*15* and *HLA-DRB1\*15*:*01* polymorphisms with response to immunosuppressive therapy (IST) in AA.

Patients with AA have been treated with IST and hematopoietic stem cell transplantation \[[@pone.0162382.ref001], [@pone.0162382.ref002]\]. However, a lack of HLA-matched sibling donors and the cost of transplantation result in most patients with AA tending to accept IST. IST contains cyclosporin (CsA), antithymocyte globulin (ATG), and antilymphocyte globulin (ALG) \[[@pone.0162382.ref001], [@pone.0162382.ref002], [@pone.0162382.ref020]\]. In addition, androgen and traditional Chinese medicine (TCM) also showed some effect on AA \[[@pone.0162382.ref021], [@pone.0162382.ref022]\]. A number of conflicting studies have reported different responses to IST in AA with *HLA-DRB1\*15* and *HLA-DRB1\*15*:*01* or without *HLA-DRB1\*15* and *HLA-DRB1\*15*:*01* polymorphisms \[[@pone.0162382.ref014]--[@pone.0162382.ref015], [@pone.0162382.ref017]--[@pone.0162382.ref018], [@pone.0162382.ref023]--[@pone.0162382.ref031]\]. When the source of hematopoietic stem cell transplantation is limited, it would be very helpful to predict which patients would benefit from IST.

As many conflicting reports were relatively small in sample size, this study increased the statistical power and evaluated evidences from various studies by summarizing them quantitatively using a meta-analytic approach, to obtain a reliable conclusion. The present study aimed to examine (1) the relationship between *HLA-DRB1* polymorphisms and AA and (2) the association of *HLA-DRB1*\*15 and *HLA-DRB1\*15*:*01* polymorphisms with response to IST in AA.

Material and Methods {#sec002}
====================

This study was performed following the Quality of Reporting of Meta-analyses guidelines \[[@pone.0162382.ref032]\] and the recommendations of the Cochrane Collaboration \[[@pone.0162382.ref033]\]. A protocol for this systematic review was published in PROSPERO with the registration number CRD42015032293([S1 File](#pone.0162382.s001){ref-type="supplementary-material"}).

Search strategy {#sec003}
---------------

This study was performed according to the standards of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) criteria \[[@pone.0162382.ref034]\]. Several databases (PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Chinese BioMedical Literature, Wangfang, and Chinese Social Sciences Citation Index databases) were searched through December 2015 for all reports on the association between HLA polymorphism and AA. The search terms were as follows: (''aplastic anemia") and (''HLA" or ''human leukocyte antigen" or "*DRB1*" or ''major histocompatibility complex" or ''MHC") and ("cyclosporine" or "antilymphocyte serum" or "immunosuppression" or "antirejection therapy" or "antithymocyte globulin") ([S2 File](#pone.0162382.s002){ref-type="supplementary-material"}). No language limitations were used in the search. In addition, references of retrieved reports were also searched, and the study authors were contacted by e-mail to identify additional studies and provide missing data.

Inclusion and exclusion criteria {#sec004}
--------------------------------

The inclusion criteria were as follows: (1) case--control or cohort study, (2) studies concerned with the associations of *HLA-DRB1\*15* and *HLA*-*DRB1\*15*:*01* polymorphisms with AA or the association of *HLA-DRB1\*15* and *HLA*-*DRB1\*15*:*01* polymorphisms with response to IST in AA, (3) sufficient data on complete response (CR) and partial response (PR) stratified by *HLA-DRB1\*15* and *HLA*-*DRB1\*15*:*01* status, and (4) studies providing sufficient data for estimating *OR* or a risk ratio (*RR*) with a 95% confidence interval (*CI*).

The exclusion criteria were as follows: (1) reviews, comments, editorials, basic science, or animal studies; (2) studies that did not reveal genotype frequency, or in which the relevant data could not be obtained after contacting with the authors, and (3) duplicate studies.

Study selection {#sec005}
---------------

The titles and abstracts were examined by two reviewers authors (S Liu and DJ Wu) independently to select eligible studies. Full-text reports of potentially relevant studies were retrieved. When data were overlapped or even duplicated, only the most recent data were included. Full texts were independently examined to decide which articles met the inclusion criteria. Discrepancies in study selection were resolved by a third reviewer (CH Ji).

Data extraction {#sec006}
---------------

Data extraction was conducted by two investigators (S Liu and Q Li) independently using a predetermined extraction form. The third participant (CH Ji) was consulted for discussion to reach an agreement concerning discrepancies. The following items were extracted from each article: first author's last name, publication year, country, number of cases and controls in case--control studies or number of cases in cohort studies, gene-detection method, genes involved, frequency of *HLA-DRB1* alleles, sex (M/F), age, treatment method, does, follow-up time, response criteria, and Newcastle--Ottawa Scale (NOS).

The outcome was *OR* in case--control studies and *RR* in cohort studies. *OR* was defined as how strongly the presence of *HLA-DRB1\*15* and *HLA-DRB1\*15*:*01* alleles in patients with AA was associated) with the presence of *HLA-DRB1\*15* and *HLA-DRB1\*15*:*01* alleles in controls. *RR* was used to show the ratio of probability of the objective response rate (*ORR*) in patients with *HLA-DRB1\*15* and *HLA-DRB1\*15*:*01* alleles to the probability of the *ORR* in patients without *HLA-DRB1\*15* and *HLA-DRB1\*15*:*01* alleles. The *ORR* was defined as the sum of CR and PR.

Quality assessment for individual studies {#sec007}
-----------------------------------------

The study used a scoring system based on the NOS to determine the quality of each article \[[@pone.0162382.ref035]\]. The NOS ranged between zero (worst) and nine stars (best). Disagreements were settled as described in the preceding section.

Statistical analysis {#sec008}
--------------------

All statistical analyses were performed using Stata 12.0 (Stata Corporation, TX, USA). Dichotomous data were reported as *OR* or *RR* (calculated using the chi-square test). The pooled *OR* or *RR* together with the 95% *CI* used for assessing the strength of association was determined using the *Z* test. Heterogeneity across studies was checked using the Cochran's *Q* statistic and the *I*^2^ test \[[@pone.0162382.ref036]\]. When *P* value greater than 0.10 for the *Q* test served as no statistical evidence for heterogeneity, the fixed-effects model was used (shown as "M-H") \[[@pone.0162382.ref037]\]; otherwise, random-effects model was used (shown as "D+L") \[[@pone.0162382.ref038]\]. Subgroup analyses were performed by regions or drugs. To evaluate the stability of outcomes, a sensitivity analysis was performed by sequential omission of individual studies. Harbord's test was conducted to evaluate the publication bias, with *P* less than 0.05 considered statistically significant \[[@pone.0162382.ref039]\]. When studying the association of *HLA-DRB1\*15* or *HLA-DRB1\*15*:*01* polymorphisms with AA, meta-regression was used to reveal whether age, region or NOS score could lead to heterogeneity.

Results {#sec009}
=======

Study characteristics {#sec010}
---------------------

The present study met the PRISMA statement requirements ([Fig 1](#pone.0162382.g001){ref-type="fig"} and [S1 Table](#pone.0162382.s004){ref-type="supplementary-material"}). A total of 1576 published studies were found examining the relationship between HLA polymorphisms and AA. A total of 68 articles were deemed relevant through reading titles and abstracts. Of these, 44 articles were excluded after reading the full text. Finally, 24 articles involving 14 case--control studies and 13 cohort studies were included. Fourteen case--control studies consisted of 938 cases and 5992 controls. Thirteen cohort studies consisted of 609 AA. Tables [1](#pone.0162382.t001){ref-type="table"} and [2](#pone.0162382.t002){ref-type="table"} list the included studies and their main characteristics. The area of these studies included Asia countries (Japan, Korea, China, Turkey, Malaysia, and Pakistan), Mexico, and Russia. The average score of NOS was 5.6 and 5.3 in case--control and cohort studies, respectively, which revealed that the methodological quality was of average level.

![Flow diagram of the study selection process.](pone.0162382.g001){#pone.0162382.g001}

10.1371/journal.pone.0162382.t001

###### Characteristics of studies included in the meta-analysis (case--control).

![](pone.0162382.t001){#pone.0162382.t001g}

  No.      Authors                                          Year   Country    Numbers   Sex (M/F)   Age     Controls   Detection methods   NOS           Genes                                
  -------- ------------------------------------------------ ------ ---------- --------- ----------- ------- ---------- ------------------- ------------- ---------------------- --------- --- ---------
  1        Song                                             2008   Korea      109       800         51/58   769/31     22 (1--80)          23 (18--50)   Healthy                PCR-SSP   6   \*15:01
  2        Sugimori[^a^](#t001fn002){ref-type="table-fn"}   2007   Japan      140       491         65/75   --         60 (12--92)         --            Healthy                PCR-SSP   6   \*15:01
  3        Huo                                              2011   China      115       2264        70/45   --         --                  --            Healthy                PCR-SSP   5   \*15
  4        Liang                                            2007   China      82        400         56/26   --         2--39               --            Healthy                PCR-SSP   6   \*15:01
  **5**    Wang                                             2014   China      43        200         24/19   101/99     40 (18--52)         34 (16--60)   Healthy                PCR-SSP   6   \*15:01
  6        Yang[^a^](#t001fn002){ref-type="table-fn"}       2002   China      45        24          28/17   --         22 (8--55)          --            Healthy                PCR-SSP   5   \*15:01
  **7**    Sun                                              2004   China      59        30          30/29   16/14      31 (10--58)         30 (15--60)   Healthy                PCR-SSP   6   \*15
  **8**    Dhaliwal                                         2011   Malaysia   33        109         20/13   --         18 (13--75)         --            BM donor and Healthy   PCR-SSP   5   \*15:01
  **9**    Rehman                                           2009   Pakistan   61        200         39/22   111/89     17 (1--48)          --            Healthy                PCR-SSP   6   \*15
  **10**   Wang                                             2014   China      96        600         56/40   --         19 (6--53)          --            BM donor               PCR-SSP   6   \*15:01
  **11**   Fernandez-Torres                                 2012   Mexico     36        201         23/13   105/96     11.7 (0.5--63)      --            National Donor         PCR-SSP   6   \*15
  **12**   Huang[^a^](#t001fn002){ref-type="table-fn"}      2007   China      40        107         26/16   --         9 (2--14)           --            Healthy                PCR-SSP   5   \*15
  **13**   Kapustin                                         2001   Russia     44        100         27/17   --         21 (4--50)          --            Healthy                PCR-SSO   5   \*15:01
  **14**   Yari                                             2008   Iran       35        466                 --         19 (5--55)                        Healthy                PCR-SSP   5   \*15

BM,bone marrow;PCR-SSO, polymerase chain reaction with sequence-specific oligonucleotide; PCR-SSP, polymerase chain reaction with sequence-specific primer.

^a^ It is included in the cohort study analysis.

10.1371/journal.pone.0162382.t002

###### Characteristics of studies included in the meta-analysis (cohort study).

![](pone.0162382.t002){#pone.0162382.t002g}

  No.      Authors    Year   Country   AA Numbers   Sex(M/F)   Age           Treatment method    Does                                                                                                                                                                               Follow-up time(M)   Detection methods   Response criteria   NOS   Genes
  -------- ---------- ------ --------- ------------ ---------- ------------- ------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- ------------------- ------------------- ----- --------------
  1        Song       2010   Korea     37           19/18      35(3--66)     CsA+ATG/ALG         \-                                                                                                                                                                                 6                   PCR-SSP             Champlin            6     \*15:01
  2        Sugimori   2007   Japan     77           --         --            CsA+ATG             CsA: 6mg/kg/d,1y; then 150--250 ng/ml, \>6 m; ATG:15mg/kg/d, 5d                                                                                                                    6                   PCR-SSP             Camitta             6     \*15:01
  3        Yang       2002   China     26           \-         22(8--55)     CsA+androgen        \-                                                                                                                                                                                 3                   PCR-SSP             Zhang               5     \*15:01
  **4**    Huang      2007   China     40           24/16      9(2--14)      CsA/CsA + ATG +MP   \-                                                                                                                                                                                 6                   PCR-SSP             Camitta             5     \*15
  **5**    Qiao       2010   China     40           22/18      36 (11--79)   CsA                 CsA: 5mg/kg/d; then 2.5--3 mg/kg/d                                                                                                                                                 6                   PCR-SSP             Zhang               6     \*15:01
  **6**    Tang       2002   China     29           9/20       24 (12--55)   CsA+androgen+TCM    CsA:6mg/kg/d,10 d;then 3mg/kg/d, \>3 m                                                                                                                                             3                   PCR-SSP             --                  5     \*15:01
  **7**    Yang       2004   China     50           36/14      32(13--45)    CsA+androgen        CsA:5mg/kg/d,3 m; then 2.5 mg/kg/d, 3 m                                                                                                                                            6                   PCR-SSO/SSP         Zhang               6     \*15:01
  **8**    Nakao      1996   Japan     111          55/56      56(10--76)    CsA/ATG             CsA: 4--6 mg/kg/d,then 150-250/ng/ml; or Horse ATG:10 or 15 mg/kg/d,5 d (Institut Melieux); or 10 or 20mg/kg/d,8 d (Upjohn); or rabbit ATG: 2.5 mg/kg/d, 5 d (Institut Melieux);   4--6                PCR-SSP             --                  5     \*15:01
  **9**    Chen       2007   China     51           30/21      32(12--79)    CsA + ATG           CsA:5mg/kg/d;then 2.5--3mg/kg/d, \>3--4 m                                                                                                                                          6                   PCR-SSP             Zhang               6     \*15/\*15:01
  **10**   Mu         2009   China     37           21/16      26 (25--57)   CsA+ATG/ALG         \-                                                                                                                                                                                 4--26               PCR-SSP             Zhang               5     \*15/\*15:01
  **11**   Yang       2004   China     35           \-         22(7--55)     CsA+ androgen+TCM   CsA:6mg/kg/d,10 d;then 3mg/kg/d, \>3 m                                                                                                                                             3                   PCR-SSP             Zhang               5     \*15:01
  **12**   Oguz       2002   Turkey    17           --         --            CsA+ ATG +MP        \-                                                                                                                                                                                 --                  --                  --                  4     \*15
  **13**   Nakao      1994   Japan     59           24/35      56(15--76)    CsA                 \-                                                                                                                                                                                 3+                  PCR-SSP             --                  5     \*15:01

AA, aplastic anemia; ALG, antilymphocyte globulin; ATG, antithymocyte globulin; CsA, cyclosporine A; MP, methylprednisolone; PCR-SSO, polymerase chain reaction with sequence-specific oligonucleotide; PCR-SSP, polymerase chain reaction with sequence-specific primer; TCM, traditional Chinese medicine.

Quantitative synthesis {#sec011}
----------------------

### Association of *HLA-DRB1\*15* and *HLA-DRB1\*15*:*01* polymorphisms with AA {#sec012}

The forest plots in Figs [2](#pone.0162382.g002){ref-type="fig"} and [3](#pone.0162382.g003){ref-type="fig"} show the main results of the meta-analysis of associations of *HLA-DRB1\*15* and *HLA-DRB1\*15*:*01* polymorphisms with AA. *HLA-DRB1\*15* and *HLA-DRB1\*15*:*01* polymorphisms conferred a significantly increased risk. The analysis of the pooled data of six case--control studies revealed a significant increase in the frequency of *HLA-DRB1\*15* polymorphism (41.0% in AA compared with 30.7% in controls). A moderate level of heterogeneity (*I*^2^ = 69.4%, *P* \< 0.01) was found. A random-effects model was used to calculate *OR*. The overall *OR* (95% *CI*) was 2.24(1.33--3.77) with *P* \< 0.01. For *HLA-DRB1\*15*:*01* polymorphism (35.6% in AA compared with 18.6% in controls), a moderate level of heterogeneity existed (*I*^2^ = 64.3%, *P* \< 0.01). A random-effects model was used. The overall *OR* (95% *CI*) was 2.50(1.73--3.62) with *P* \< 0.01.

![Forest plot of *HLA-DRB1\*15* polymorphism and aplastic anemia.](pone.0162382.g002){#pone.0162382.g002}

![Forest plot of *HLA-DRB1\*15*:*01* polymorphism and aplastic anemia.](pone.0162382.g003){#pone.0162382.g003}

The subgroup analysis of *HLA-DRB1\*15* and *HLA-DRB1\*15*:*01* polymorphisms showed similar results. The *OR* (95% *CI*) values of *HLA-DRB1\*15* and *HLA-DRB1\*15*:*01* were 2.00(1.53--2.61) from fixed---effects model ([Fig 2](#pone.0162382.g002){ref-type="fig"}) and 2.37 (1.59--3.53) from random---effects model, respectively, for the Asian patients (*P* \< 0.01) ([Fig 3](#pone.0162382.g003){ref-type="fig"}).

### Response to IST in AA {#sec013}

A summary of the meta-analysis findings on the association of *HLA*-*DRB1\*15* and *HLA*-*DRB1\*15*:*01* polymorphisms with response to IST in AA is provided in Figs [4](#pone.0162382.g004){ref-type="fig"} and [5](#pone.0162382.g005){ref-type="fig"}. The response to IST was significantly higher in *HLA*-*DRB1\*15*^*+*^ patients (84.7%) than in *HLA*-*DRB1\*15−* patients (49.3%), with no heterogeneity (*I*^2^ = 0%, *P* = 0.715). A fixed-effects model was used for calculating *RR*. The overall *RR* (95% *CI*) was 1.72 (1.30--2.29) (*P* \< 0.01).

![Forest plot of relative ratios for overall response rate between *HLA-DRB1\*15*^*+*^ and *HLA-DRB1\*15−* patients.](pone.0162382.g004){#pone.0162382.g004}

![Forest plot of relative ratios for overall response rate between *HLA-DRB1\*15*:*01*^*+*^ and *HLA-DRB1\*15*:*01−* patients.](pone.0162382.g005){#pone.0162382.g005}

For *HLA*-*DRB1\*15*:*01*, the response to IST was significantly higher in *HLA*-*DRB1\*15*:*01*^*+*^ patients (78.4%) than in *HLA*-*DRB1\*15*:*01−* patients (47.9%), with a moderate level of heterogeneity (*I*^2^ = 52.8%, *P* = 0.016). A random-effects model was used for calculating *RR*. The overall *RR* (95% *CI*) was 1.59 (1.29--1.96) (*P* \< 0.01).

In the CsA therapy subgroup, an improvement in 33 of 40 *HLA*-*DRB1\*15*:*01*^*+*^ patients was observed, while the response rate was 48/111 in *HLA*-*DRB1\*15*:*01−* patients, with no heterogeneity (*I*^2^ = 0%, *P* = 0.956). A fixed-effects model was used for calculating *RR*. The overall *RR* (95% *CI*) was 1.89 (1.47--2.45) with *P* \< 0.01. In the CsA plus ATG/ALG group, a moderate level of heterogeneity was found (*I*^2^ = 52.1%, *P* = 0.099). A random-effects model was used for calculating *RR*. The overall *RR* (95% CI) was 1.53 (1.07--2.20) with *P* \< 0.01. In the CsA + androgen group, no heterogeneity was found (*I*^2^ = 52.8%, *P* = 0.146). A fixed-effects model was used for calculating *RR*. The overall *RR* (95% *CI*) was 3.56 (1.87--6.76) with *P* \< 0.01. In the CsA + androgen + TCM group, there is no significant difference between groups ([Fig 5](#pone.0162382.g005){ref-type="fig"}).

Sensitivity analyses {#sec014}
--------------------

A single report involved in the meta-analysis was removed each time to reflect the influence of the individual dataset on the pooled *OR* or *RR*, and the corresponding pooled *OR* and *RR* were not materially changed (data not shown), indicating that the results were statistically robust.

Publication bias {#sec015}
----------------

The shape of the Harbord's funnel plot showed a relatively symmetric distribution with no publication bias by statistical evidence (*P* \> 0.05, shown in [Fig 6](#pone.0162382.g006){ref-type="fig"}), indicating that the results of this study were statistically robust.

![Publication bias plots using the Harbord's test.\
(A) Publication bias plot of *HLA-DRB1\*15* polymorphism and aplastic anemia. (B) Publication bias plot of HLA-*DRB1*\*15:01 polymorphism and aplastic anemia. (C) Publication bias plot of RR between *HLA-DRB1\*15*^*+*^ and *HLA-DRB1\*15−* patients. (D) Publication bias plot of RR between *HLA-DRB1\*15*:*01*^*+*^ and *HLA-DRB1\*15*:*01−* patients.](pone.0162382.g006){#pone.0162382.g006}

Influence of age at diagnosis, region, and NOS score {#sec016}
----------------------------------------------------

The results of meta-regression analysis showed that age, region, or NOS score did not account for heterogeneity when studying the association of *HLA-DRB1\*15* or *HLA-DRB1\*15*:*01* polymorphisms with AA ([Table 3](#pone.0162382.t003){ref-type="table"}).

10.1371/journal.pone.0162382.t003

###### Meta-regression.

![](pone.0162382.t003){#pone.0162382.t003g}

              *HLA-DRB1\*15*   *HLA-DRB1\*15*:*01*            
  ----------- ---------------- --------------------- -------- -------
  Age         -0.093           0.067                 -0.001   0.919
  Region      1.542            0.092                 -0.495   0.484
  NOS score   0.098            0.912                 -0.784   0.103

Discussion {#sec017}
==========

This study systematically reviewed the articles on the relationship of *HLA*-*DRB1\*15* and *HLA*-*DRB1\*15*:*01* polymorphisms with response to IST in AA. Based on the search criteria, 24 studies involving 14 case--control studies and 13 cohort studies were included in the final meta-analysis. A total of 938 cases and 5992 controls from case--control studies were used to find the relationship of *HLA*-*DRB1\*15* and *HLA*-*DRB1\*15*:*01* polymorphisms with AA in the pooled analyses. Moreover, 609 AA in cohort studies were used to discuss the association of *HLA*-*DRB1\*15* and *HLA*-*DRB1\*15*:*01* polymorphisms with response to IST in AA. This study was perhaps the first meta-analysis to explore the relationship of *DRB1\*15* and *DRB1\*15*:*01* with response to IST in AA.

Of the six studies about the associations between *HLA*-*DRB1\*15* polymorphisms and AA and eight studies about the associations between *HLA*-*DRB1\*15*:*01* polymorphisms and AA, the majority indicated that *HLA*-*DRB1\*15* and *HLA*-*DRB1\*15*:*01* polymorphisms might be potential risk factors for AA \[[@pone.0162382.ref006]--[@pone.0162382.ref010], [@pone.0162382.ref014]--[@pone.0162382.ref015], [@pone.0162382.ref018]--[@pone.0162382.ref019], [@pone.0162382.ref024]\], but four studies indicated no association of *HLA*-*DRB1*\*15 and *HLA*-*DRB1*\*15:01 polymorphisms with AA \[[@pone.0162382.ref005]--[@pone.0162382.ref006], [@pone.0162382.ref012]--[@pone.0162382.ref013],[@pone.0162382.ref016]\]. The pooled results of the meta-analysis were consistent with most studies, which indicated *HLA*-*DRB1*\*15 and *HLA*-*DRB1*\*15:01 polymorphisms as potential risk factors for AA (*OR* = 2.24, 2.50, respectively; Figs [2](#pone.0162382.g002){ref-type="fig"} and [3](#pone.0162382.g003){ref-type="fig"}). In subgroup analysis, region was the reason for heterogeneity in *HLA*-*DRB1\*15* but not in *HLA*-*DRB1\*15*:*01*. In addtion, there was only one small non-Asians group in each analysis. So it is more valid to say that these associations were found in Asian populations.

Of the 4 studies about the associations between *HLA*-*DRB1\*15* polymorphisms and response to IST in AA and 11 studies about the associations between *HLA*-*DRB1\*15*:*01* polymorphisms and response to IST in AA, the majority indicated that patients with AA who carried *HLA*-*DRB1\*15* or *HLA*-*DRB1\*15*:*01 alleles* might have a good response rate for the IST \[[@pone.0162382.ref014]--[@pone.0162382.ref015], [@pone.0162382.ref023]--[@pone.0162382.ref024], [@pone.0162382.ref026]--[@pone.0162382.ref027], [@pone.0162382.ref030]--[@pone.0162382.ref031]\]. Seven studies indicated no association of *HLA*-*DRB1\*15* and *HLA*-*DRB1\*15*:*01* polymorphisms with IST in AA \[[@pone.0162382.ref017]--[@pone.0162382.ref018], [@pone.0162382.ref025], [@pone.0162382.ref028]--[@pone.0162382.ref030]\]. The pooled results showed that the response rate was significantly higher in *HLA*-*DRB1\*15*^*+*^ and *HLA*-*DRB1\*15*:*01*^*+*^ patients than in *HLA*-*DRB1\*15−* and *HLA*-*DRB1\*15*:*01−* patients (84.7% vs 49.3% and 78.4% vs 47.9%, *RR* = 1.72 and 1.59, respectively). It means that *HLA*-*DRB1\*15*^*+*^ and *HLA*-*DRB1\*15*:*01*^*+*^ patients with AA treated with IST were more sensitive than *HLA*-*DRB1\*15−* and *HLA*-*DRB1\*15*:*01−* patients.

In a subgroup analysis, *HLA*-*DRB1\*15*:*01*^*+*^ patients treated with CsA, CsA + ATG/ALG, or CsA + androgen showed a higher response rate than *DRB1\*15*:*01−* patients (*RR* = 1.89, 1.53 and 3.56, respectively). Only two articles included the CsA + androgen subgroup. Hence, the results needed further investigation. A negative result was obtained in CsA + androgen + TCM group. It is known that TCM combine different kinds of herbs that might have cause the clinical heterogeneity. Further researches and analyses are needed to validate the findings.

Heterogeneity is a potential issue that may affect the results of all meta-analyses. Statistical heterogeneity existed among some analyses in the present study. Several methods were applied to examine whether the results were robust. First, we considered region, mean or median age or NOS score as a covariate in the meta-regression analysis. The results indicated that these factors are not statistically significant (P\>0.05) for heterogeneity when studying the association between *DRB1\*15* or *DRB1\*15*:*01* polymorphisms and AA. Second, subgroup analyses by region or drugs and sensitivity analyses were performed. It indicated that drug groups led to heterogeneity when studying the association of *HLA*-*DRB1\*1501* polymorphisms with response to IST in patients with AA. Additionally, the region was a significant factor for heterogeneity when studying the association between *HLA*-*DRB1\*15* polymorphisms and AA. However, the region was not a significant factor for heterogeneity when studying the association between *HLA*-*DRB1\*15*:*01* polymorphisms and AA.

Both English and Chinese language reports were identified, obtained, and included in this analysis to avoid the local literature bias\[[@pone.0162382.ref040]\]. However, several limitations still could not be ignored. First, the results were based on unadjusted analysis. Some factors such as the dose, product and biological characteristics of the xenoantisera, short telomeres, younger age, absolute reticulocyte count, absolute lymphocyte count, normal cytogenetics, and paroxysmal nocturnal hemoglobinuria clone, were also associated with a higher response rate \[[@pone.0162382.ref001], [@pone.0162382.ref041]\]. However, information was not available to perform more detailed analysis. As a result, these factors were not considered in this study. Further researches are still needed in the future to figure out the complex effect of the aforementioned factors and *HLA*-*DRB1\*15*, *and HLA*-*DRB1\*15*:*01* polymorphisms. Second, HLA typing was performed by PCR with sequence-specific primers in most included articles, but two reports involved PCR with sequence-specific oligonucleotide primers. The typing methods were not identical between different researches, which might have led to the heterogeneity in the present analysis. Third, probably most of the *HLA*-*DRB1\*15* patients were actually *HLA*-*DRB1\*15*:*01*, but it was not confirmed. Finally, because of the low incidence of *DRB1* genotype, limited studies were available for inclusion in this meta-analysis. Only few articles were found about other ethnicities. Hence, it could not be concluded whether *HLA*-*DRB1\*15* and *HLA*-*DRB1\*15*:*01* polymorphisms were different in those ethnic groups.

Conclusions {#sec018}
===========

*HLA*-*DRB1\*15* and *HLA*-*DRB1\*15*:*01* polymorphisms might be associated with increased AA risk in Asians. IST might be more effective in Asian patients with *HLA*-*DRB1\*15* and *HLA*-*DRB1\*15*:*01* polymorphisms than in Asian patients without *HLA*-*DRB1\*15* and *HLA*-*DRB1\*15*:*01* polymorphisms. More articles with adequate methodological quality on gene--gene and gene--environment interactions and gene treatment may eventually lead to valid results in the future.
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